Group 1 - Morgan Stanley raised the target price for Innovent Biologics (01801.HK) from HKD 74 to HKD 84, maintaining an "Overweight" rating [1] - The increase in target price is attributed to upcoming catalysts and updates following the American Society of Clinical Oncology (ASCO) meeting [1] - The positive data on overall survival for IBI363 presented at the ASCO conference is expected to drive further stock performance [1] Group 2 - Morgan Stanley anticipates that the drug MaShidu will receive approval in China within 1 to 2 months, potentially providing additional stock options [1] - The sales forecast for IBI363 has been raised by approximately 95% post-ASCO meeting, along with an increase in pipeline valuation [1] - The firm holds a moderate sales expectation for MaShidu in 2025 [1]
摩根大通升信达生物目标价至84港元 重申增持评级